Collegium (COLL) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$808.2M

Revenue (quarter)

$199.9M

Revenue growth (year over year)

+6.32%

Gross profit (trailing twelve months)

$485.1M

Gross margin

60.02%

Net income (trailing twelve months)

$47.9M

Net income (quarter)

−$15.1M

Net income growth (year over year)

−225.60%

Net margin

5.93%

Return on equity

17.61%

EPS (trailing twelve months)

$1.51

Book value per share

$9.60

P/E (trailing twelve months)

14.63

Price to book

2.25

Debt to assets

85.40%

Payout ratio

—

Dividend yield

—

Company profile

Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.

• Is Collegium (COLL) profitable?

  Yes. Collegium earned $47.9M in net income over the trailing twelve months, a net margin of 5.93%.

• How much revenue does Collegium (COLL) make?

  Collegium generated $808.2M in revenue over the trailing twelve months, up 6.32% year over year.

• What is COLL's P/E ratio?

  Collegium trades at 14.6 times trailing twelve-month earnings, on an EPS of $1.51.

• How do I buy stock in Collegium (COLL)?

  COLL trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.